Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

Melanoma Clinical Trial

Official title:

A Phase I Study of PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01462773
• Other study ID #: OSU-04105
• Secondary ID: NCI-2011-03174
• Status: Completed
• Phase: Phase 1
• First received: October 19, 2011
• Last updated: December 30, 2014
• Start date: January 2006
• Est. completion date: April 2013

Study information

• Verified date: December 2014
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.

Description:

The primary objective of this study is to:

• Determine the safety, tolerability and DLTs of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.

The secondary objectives of this study are to:

• Document any objective anti-tumor responses that may occur in response to this treatment regimen.

• Document the time to tumor progression in patients receiving this treatment regimen.

• Measure levels of the cell cycle proteins p21 and p27 in PBMCs and tumor biopsies obtained pre-study and during week 4 of Cycle 1 (Day 26).

• Conduct histologic evaluations of microvessel density, tumor apoptosis and lymphocytic infiltrates within tumor biopsies obtained pre- and post-study.

• Measure plasma levels of bFGF and VEGF over the course of the study.

• Monitor the effects of proteasome inhibition on the biological activity of IFN-α within immune cells by measuring Jak-STAT signal transduction in patient PBMCs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: April 2013
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• must have histological or cytological diagnosis of cutaneous melanoma and clinical evidence of metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. Patients who have had resected metastases will also be eligible provided they have measurable disease.

• have measurable disease. Measurable disease is defined as the presence of at least one measurable lesion.

• ECOG performance status = 2 (Karnofsky = 60%).

• Female subjects must be either surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subjects must agree to use an acceptable method for contraception for the duration of the study.

• Patients must have normal organ and marrow function.

• Prior Therapy: Patients with an ECOG performance status of = 2 will be eligible for this protocol regardless of the number of prior treatments provided they have recovered from the reversible effects of prior therapy. Patients are permitted to have received therapy with adjuvant IFN-a2b, if it was completed > 6 months prior to enrollment in the current study.

• Patients with brain metastases are eligible for entry into the study, but must have received definitive therapy consisting of external beam radiation therapy, gamma knife therapy or surgical resection and be clinically stable. Four weeks after the definitive therapy is completed, repeat MRI or CT scans must demonstrate stabilization of disease, and there must be no requirement for Decadron. If the patient does not have brain metastases, then only one brain CT or MRI is required prior to enrollment on study.

Exclusion Criteria:

• Patients meeting any of the following exclusion criteria are not to be enrolled in the study.

• Patient has a platelet count of < 100 × 109/L within 14 days before enrollment.

• Patient has an absolute neutrophil count of < 1.0 x 109/L within 14 days before enrollment.

• Patient has a calculated or measured creatinine clearance of < 30 mL/minute within 14 days before enrollment.

• Patient has history of significant brain metastases or other clinically significant central nervous system disease.

• Patient has =Grade 2 peripheral neuropathy within 14 days before enrollment.

• Patient has hypersensitivity to bortezomib, boron or mannitol.

• Patients with evidence of proteinuria on urinalysis.

• Female subject is pregnant or breast-feeding.

• Received other investigational drugs with 14 days before enrollment.

• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.

• History of serious psychiatric illness that might be exacerbated by IFN-a-2b.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Bortezomib
VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
• Interferon Alfa-2b
I = IFN-a-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-a will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-a-2b alone, no VELCADE will be administered during Week 0.

Locations

Country	Name	City	State
United States	Ohio State University	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE 3rd. A phase I trial of bortezomib and interferon-a-2b in metastatic melanoma. J Immunother. 2014 Jan;37( — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine Dose Limiting Toxicities (DLTs) of VELCADE When Administered in Combination With IFN-a-2b to Patients With Metastatic Malignant Melanoma.	A standard method for the design of this study. Initially, three patients will be treated at a starting dose of VELCADE (1.0 mg/m2). If one of the three patients demonstrates a DLT, then an additional 3 patients will be treated at that dose level. If only one of the six show DLT, then the next cohort of three patients will be entered at the next dose level (1.3 mg/m2). If two or more of the six demonstrate DLT, no further patients will be treated at that dose level. The highest dose level at which less than 2 patients experienced DLT will be expanded to six patients.	up to 25 weeks or until disease progression	Yes
Secondary	Document Any Objective Anti-tumor Responses and Time to Tumor Progression That May Occur in Response to This Treatment Regimen.	Measure levels of the cell cycle proteins p21 and p27 in PBMCs and tumor biopsies obtained pre-study and during week 4 of Cycle 1 (Day 26).; Conduct histologic evaluations of microvessel density, tumor apoptosis and lymphocytic infiltrates within tumor biopsies obtained pre- and post-study.; Measure plasma levels of bFGF and VEGF over the course of the study.; Monitor the effects of proteasome inhibition on the biological activity of IFN-a within immune cells by measuring Jak-STAT signal transduction in patient PBMCs.	up to 25 weeks	Yes

External Links

•   Jamesline